NEW YORK, March 13, 2013 /PRNewswire/ --
Today, Investors Alliance announced new research reports highlighting Abbott Laboratories (NYSE: ABT), Stryker Corporation (NYSE: SYK), St. Jude Medical, Inc. (NYSE: STJ), Cardiovascular Systems Inc (NASDAQ: CSII) and MAKO Surgical Corp. (NASDAQ: MAKO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Abbott Laboratories Research Report
Abbott Laboratories has released new data indicating that Abott's Absorb Bioresorbable Vascular helps improve blood vessel movement in patients with coronary heart disease (CAD). Absorb is the first of its kind device that works by opening clogged vessels and restoring blood flow. Unlike metallic stents, Absorb dissolve over time, potentially allowing natural blood flow to return. Absorb is already commercially available in Europe and other international market, but is still an investigational device in the United States. Separately, Abbott announced data from the EVEREST II study, showing that Abbott's MitraClip System may help treat patients who are not allowed to go through mitral valve surgery due to risk of mortality. With these products, Abbott is well-positioned to capitalize on the United States' vascular market. The Full Research Report on Abbott Laboratories - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/9cb0_ABT]
Stryker Corporation Research Report
Stryker recently completed its acquisition of Trauson Holdings Company Limited, a manufacturer of trauma-related products in China. This acquisition is a critical step in helping Stryker broadens its presence in the region, though the financial benefits of this acquisition is not expected to impact Stryker's earnings for 2013. Due to this acquisition, Goldman Sachs reiterated its Buy rating on Stryker Corporation and promptly increased its price target from $71 to $72. Goldman Sachs notes that this acquisition could be accretive for Stryker in the long-term, especially if Stryker "proves successful at leveraging Trauson's existing channels in China to sell a broader product range." Stryker's deepened presence in emerging markets helps position it for future growth. The Full Research Report on Stryker Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/8335_SYK]
St. Jude Medical, Inc. Research Report
St. Jude Medical makes its way to Japan by launching its ILUMIEN OPTIS System in the region. The product is used to help physicians make personalized stenting decisions based on each patient's unique anatomy and disease state. According to William Phillips, president of St. Jude Medical Japan, the company is excited about expanding its reach of the ILUMIEN OPTIS in Japan, a world leader in imaging technology. In Japan, around 245,000 Percutaneous Coronary Intervention (PCI) procedures are performed to treat cardiovascular disease, and 80 percent are said to use the technology, showing the potential market for ILUMIEN OPTIS. Aside from this, St. Jude Medical's AMPLATZER Cardiac Plug, a product for the prevention of stroke, is said to be on track with its development, showing continued strength in the company's atrial fibrillation business. These latest developments are in line with the company's commitment to deliver strong EPS growth without sacrificing investment for its pipeline. The Full Research Report on St. Jude Medical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/d3fb_STJ]
Cardiovascular Systems Inc Research Report
Cardiovascular Systems made headlines after the company presented results from its ORBIT II study of severely calcified coronary lesions. The results showed that CSI's orbital atherectomy technology may be a viable treatment option for patients with severe calcified lesions. The results showed study endpoints were met by a significant margin. These results make the prospects of the company's coronary business seem brighter, helping it move forward towards its goal of filing the product for FDA approval. The company believes that the market opportunity for this technology is estimated to exceed $1.5 billion annually in the US alone. Shares of Cardiovascular Systems jumped 16.55 percent following the release of these results. The Full Research Report on Cardiovascular Systems Inc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/8bf1_CSII]
MAKO Surgical Corp. Research Report
MAKO has been steadily gaining after the robotic arm and orthopedic implants manufacturer reported impressive fourth quarter and full year 2012 results. Its revenue for the year totaled at $102.7 million, showing an increase of 22 percent over 2011. This increase was due to stronger sales of RIO systems and higher MAKOplasty procedure volumes. At present, the company is currently training physicians to perform its procedures to increase the volume of MAKOplasty procedures, drive sales of its RIO systems, and increase profitability. The Full Research Report on MAKO Surgical Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/1687_MAKO]
Consider Investors Alliance
Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks.
Contact: Patricia Byers
Email: [email protected]